Characteristics of 157 patients with progression or relapse of a BL/B-AL during or after BFM-type chemotherapy diagnosed between 1986 and 2016
| . | All . | Until 2000 . | From 2001 . | P . |
|---|---|---|---|---|
| All patients | 157 | 82 | 75 | |
| Sex | ||||
| Male | 127 (81%) | 66 (80%) | 61 (81%) | 1.0 |
| Female | 30 (19%) | 16 (20%) | 14 (19%) | |
| Median age at relapse, y | 9.9 (2.9-19.6) | 9.9 (2.9-19.6) | 9.6 (3.2-18.7) | .91 |
| Median time from diagnosis to relapse, y | 0.4 (0-2) | 0.4 (0-2) | 0.4 (0.1-2) | .63 |
| Progression/relapse | ||||
| During first-line | 81 (52%) | 53 (65%) | 28 (37%) | .001 |
| After first-line | 76 (48%) | 29 (35%) | 47 (63%) | |
| Initial stage* | ||||
| I | 2 (1%) | 2 (3%) | .53 | |
| II | 6 (4%) | 2 (2%) | 4 (5%) | |
| III | 61 (39%) | 33 (40%) | 28 (37%) | |
| IV | 20 (13%) | 12 (15%) | 8 (11%) | |
| B-AL | 64 (41%) | 35 (43%) | 29 (41%) | |
| NA | 4 (3%) | — | 4 (5%) | |
| CNS (initial) | ||||
| No | 117 (75%) | 61 (74%) | 56 (75%) | 1.0 |
| Yes | 40 (25%) | 21 (26%) | 19 (25%) | |
| Initial therapy branch | ||||
| R1/R2 | 18 (12%) | 4 (5%) | 14 (19%) | .01 |
| R3/R4 | 137 (88%) | 76 (95%) | 61 (81%) | |
| BM-relapse | ||||
| No | 98 (62%) | 49 (60%) | 49 (65%) | .51 |
| Yes | 59 (38%) | 33 (40%) | 26 (35%) | |
| CNS relapse | ||||
| No | 115 (73%) | 62 (76%) | 53 (71%) | .59 |
| Yes | 42 (27%) | 20 (24%) | 22 (29%) | |
| Local relapse | ||||
| No | 94 (60%) | 54 (66%) | 40 (53%) | .14 |
| Yes | 63 (40%) | 28 (34%) | 35 (47%) | |
| Other relapse | ||||
| No | 115 (73%) | 66 (80%) | 49 (65%) | .05 |
| Yes | 42 (27%) | 16 (20%) | 26 (35%) |
| . | All . | Until 2000 . | From 2001 . | P . |
|---|---|---|---|---|
| All patients | 157 | 82 | 75 | |
| Sex | ||||
| Male | 127 (81%) | 66 (80%) | 61 (81%) | 1.0 |
| Female | 30 (19%) | 16 (20%) | 14 (19%) | |
| Median age at relapse, y | 9.9 (2.9-19.6) | 9.9 (2.9-19.6) | 9.6 (3.2-18.7) | .91 |
| Median time from diagnosis to relapse, y | 0.4 (0-2) | 0.4 (0-2) | 0.4 (0.1-2) | .63 |
| Progression/relapse | ||||
| During first-line | 81 (52%) | 53 (65%) | 28 (37%) | .001 |
| After first-line | 76 (48%) | 29 (35%) | 47 (63%) | |
| Initial stage* | ||||
| I | 2 (1%) | 2 (3%) | .53 | |
| II | 6 (4%) | 2 (2%) | 4 (5%) | |
| III | 61 (39%) | 33 (40%) | 28 (37%) | |
| IV | 20 (13%) | 12 (15%) | 8 (11%) | |
| B-AL | 64 (41%) | 35 (43%) | 29 (41%) | |
| NA | 4 (3%) | — | 4 (5%) | |
| CNS (initial) | ||||
| No | 117 (75%) | 61 (74%) | 56 (75%) | 1.0 |
| Yes | 40 (25%) | 21 (26%) | 19 (25%) | |
| Initial therapy branch | ||||
| R1/R2 | 18 (12%) | 4 (5%) | 14 (19%) | .01 |
| R3/R4 | 137 (88%) | 76 (95%) | 61 (81%) | |
| BM-relapse | ||||
| No | 98 (62%) | 49 (60%) | 49 (65%) | .51 |
| Yes | 59 (38%) | 33 (40%) | 26 (35%) | |
| CNS relapse | ||||
| No | 115 (73%) | 62 (76%) | 53 (71%) | .59 |
| Yes | 42 (27%) | 20 (24%) | 22 (29%) | |
| Local relapse | ||||
| No | 94 (60%) | 54 (66%) | 40 (53%) | .14 |
| Yes | 63 (40%) | 28 (34%) | 35 (47%) | |
| Other relapse | ||||
| No | 115 (73%) | 66 (80%) | 49 (65%) | .05 |
| Yes | 42 (27%) | 16 (20%) | 26 (35%) |
BM, bone marrow; NA, not available because of missing initial lumbar puncture.
According to St. Jude’s staging system.